GLAXOSMITHKLINE BIOLOGICALS SA - Belgium 

Ranking results:

Past rankings:

2019
Criterium:Position:
Overall Score:> 1000
Total Number of Projects:> 1000
2014
Criterium:Position:
Overall Score:> 1000
Networking Rank (Reputation):> 1000
2010
Criterium:Position:
Overall Score:900-1000
Total Project Funding per Partner:> 1000
Total Number of Projects:> 1000
Total Project Funding:700-800
Networking Rank (Reputation):> 1000
Partner Constancy:> 1000
Project Leadership Index:> 1000
Diversity Index:800-900
2009
Criterium:Position:
Overall Score:> 1000
Total Project Funding per Partner:> 1000
Total Number of Projects:> 1000
Total Project Funding:> 1000
Partner Constancy:> 1000
Project Leadership Index:> 1000
Diversity Index:> 1000
2008
Criterium:Position:
Overall Score:> 1000
Total Project Funding per Partner:> 1000
Total Number of Projects:> 1000
Total Project Funding:> 1000
Partner Constancy:> 1000
Project Leadership Index:> 1000
Diversity Index:> 1000
2007
Criterium:Position:
Overall Score:> 1000
Total Project Funding per Partner:500-600
Total Number of Projects:> 1000
Total Project Funding:200-300
Networking Rank (Reputation):800-900
Partner Constancy:> 1000
Project Leadership Index:> 1000
Diversity Index:> 1000

Ranking timeline:

Project Participation Performance(2010-01-01 - 2024-12-31 ):

Total Project Funding:

Total funding allocated to projects this organisation participated or coordinated

Funding per Partner:

Since 2014 individual funding per partner. If data is not available at CORDIS: total funding / No of participants.

Projects:

Leadership:

Total number of projects: 19
As coordinator: 2
As participant: 14
Sole participant: 3
Coordinator / Participant Ratio: 0.14*

*Ratio includes only projects with > 2 partners

Summary:

Total project funding [€]:Projects [No]:
Year:coordinator*participant*per partner  as coordinatoras participant
2021 0 28.844.375 0 3
2019 0 5.499.882 0 1
2017 0 25.810.243 0 3
2016 0 28.850.000 0 2
2015 0 18.200.000 0 1
2014 21.153.216 0 17.375.837 2
2013 339.600 10.313.706 1.151.600 2 2
2011 0 29.980.670 0 1
2010 220.500 11.996.730 370.500 1 1
*n.b.: These numbers represent the total amount of funds allocated to projects this institution has participated in, not the funding allocated to this institution

Networking:

Partners:

Institution:Projects [No]:
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD10
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE7
DEPARTMENT OF HEALTH6
ISTITUTO SUPERIORE DI SANITA6
RIJKSINSTITUUT VOOR VOLKSGEZONDHEID EN MILIEU6
STATENS SERUM INSTITUT6
ACADEMISCH ZIEKENHUIS LEIDEN5
PFIZER LIMITED5
SANOFI PASTEUR5
UNIVERSITAIR MEDISCH CENTRUM UTRECHT5
ACADEMISCH ZIEKENHUIS GRONINGEN4
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE4
INSTITUT PASTEUR4
UNIVERSITE DE GENEVE4
ASSOCIATION INTERNATIONALE DE STANDARDISATION BIOLOGIQUE POUR L'EUROPE3
FUNDACION PARA EL FOMENTO DE LA INVESTIGACION SANITARIA Y BIOMEDICA DE LA COMUNITAT VALENCIANA3
INSTITUT PASTEUR DE LILLE3
INSTITUT SCIENTIFIQUE DE SANTE PUBLIQUE3
MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN EV3
SANOFIAVENTIS3
STICHTING TUBERCULOSIS VACCINE INITIATIVE3
UNIVERSITE LIBRE DE BRUXELLES3
UNIVERSITEIT ANTWERPEN3
UNIVERSITEIT UTRECHT3
ASTON UNIVERSITY2
ASTRAZENECA AB2
BIOMERIEUX2
BUNDESINSTITUT FUR IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL2
COMMISSARIAT A L'ENERGIE ATOMIQUE2
DANMARKS TEKNISKE UNIVERSITET2
EBERHARD KARLS UNIVERSITAET TUEBINGEN2
EDUCATIONAL FOUNDATION YONSEI UNIVERSITY2
EUROPEAN VACCINE INITIATIVE EWIV2
FONDAZIONE PER L'ISTITUTO DI RICERC A IN BIOMEDICINA2
FOUNDATION BIOMEDICAL PRIMATE RESEARCH CENTRE2
FUNDACIO INSTITUT DE INVESTIGACIO EN CIENCIES DE LA SALUT GERMANS TRIAS I PUJOL2
GOETEBORGS UNIVERSITET2
HEALTH PROTECTION AGENCY2
HOOKIPA BIOTECH2
HOSPICES CANTONAUX CHUV2
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE2
JANSSEN PHARMACEUTICA NV2
JANSSEN VACCINES & PREVENTION BV2
KLINIKUM DER UNIVERSITAET ZU KOELN2
LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE2
MEDICAL RESEARCH COUNCIL2
MINISTERIE VAN VOLKSGEZONDHEID WELZIJN EN SPORT2
NOVAVAX INC2
P95 CVBA2
SCLAVO VACCINES ASSOCIATION2
SERVIZO GALEGO DE SAUDE2
SYNAPSE RESEARCH MANAGEMENT PARTNERS SL2
TERVEYDEN JA HYVINVOINNIN LAITOS2
THE UNIVERSITY OF EDINBURGH2
THE UNIVERSITY OF TUEBINGEN2
UNIVERSIDAD DE ZARAGOZA2
UNIVERSITA DEGLI STUDI DI SIENA2
UNIVERSITAET INNSBRUCK2
UNIVERSITAET ULM2
UNIVERSITAET ZUERICH2
UNIVERSITY COLLEGE LONDON2
UNIVERSITY OF SURREY2
VARSINAISSUOMEN SAIRAANHOITOPIIRIN KUNTAYHTYMA2
VISMEDERI2
2CONTROL APS1
ABBOTT BIOLOGICALS BV1
ABERA BIOSCIENCE AB1
AERAS GLOBAL TB VACCINE FOUNDATION1
AGENTSCHAP COLLEGE TER BEOORDELING VAN GENEESMIDDELEN1
ALTA RICERCA E SVILUPPO IN BIOTECNOLOGIE SRL ALTA1
APITOPE INTERNATIONAL NV1
ARENAVAX1
ARES GENETICS1
ASTRAZENECA1
AUSTRIAN AGENCY FOR HEALTH AND FOOD SAFETY1
AZIENDA OSPEDALIERA UNIVERSITARIA POLICLINICO PAOLO GIACCONE DI PALERMO1
Bangor University1
BAYERISCHE JULIUS MAXIMILIANS UNIVERSITAET WUERZBURG1
BERNHARD NOCHT INSTITUT FUER TROPENMEDIZIN1
BIONEEDLE TECHNOLOGIES GROUP BV1
BOEHRINGER INGELHEIM VETMEDICA1
BORD OSPIDEIL NAOIMH SHEAMUIS1
CENTRE D'ETUDE ET DE RECHERCHES VETERINAIRES ET AGROCHIMIQUES1
CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS1
COMMISSION OF THE EUROPEAN COMMUNITIES DIRECTORATE GENERAL JOINT RESEARCH CENTRE JRC1
CONFEDERATION OF MENINGITIS ORGANISATIONS1
CROSSBETA BIOSCIENCES BV1
CUREVAC1
DA VOLTERRA SAS1
DUOTOL AB1
EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH1
EMORY UNIVERSITY NON PROFIT CORP1
ENPICOM BV1
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM1
EURICE EUROPEAN RESEARCH AND PROJECT OFFICE1
EUROPEAN VACCINE INITIATIVE EV1
FEDERATION EUROPEENNE D'ASSOCIATIONS ET D'INDUSTRIES PHARMACEUTIQUES1
FOLKEHELSEINSTITUTTET1
FONDAZIONE HUMANITAS PER LA RICERCA1
FONDAZIONE PENTA FOR THE TREATMENT AND CARE OF CHILDREN WITH HIV ANDRELATED DISEASES ONLUS1

Constancy:

Total number of partners: 333
Partner loyalty:
Frequent Partner: (> 2 projects): 107
Rare Partner: 226
Frequent / Rare Partner Ratio: 0.47

Project overview:

Start dateProjectacronymrolefundingpartners
2021-11-01Predicting the Impact of Monoclonal Antibodies & Vaccines on Antimicrobial Resistance PrIMAVeRaparticipant6.500.00019
2021-11-01Preparing for RSV Immunisation and Surveillance in Europe PROMISEparticipant3.744.37522
2021-09-01Innovations to accelerate vaccine development and manufacture Inno4Vacparticipant18.600.00041
2019-01-01Vaccines and Infectious Diseases in the Ageing PopuLation VITALparticipant5.499.88224
2017-11-01Combatting Bacterial Resistance in Europe - Clostridium Difficile Infections COMBACTE-CDIparticipant2.312.30514
2017-07-01Development of Robust and Innovative Vaccine Effectiveness DRIVEparticipant8.999.81315
2017-01-01REspiratory Syncytial virus Consortium in EUrope - Sofia ref.: 116019 RESCEUparticipant14.498.12518
2016-03-01Vaccine lot to Vaccine lot comparison by consistancy testing - Sofia ref.: 115924 VAC2VACparticipant7.850.00023
2016-03-01PERtussIS COrrelates of Protection Europe - Sofia ref.: 115910 PERISCOPEparticipant21.000.00024
2015-01-01TBVAC2020; Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development TBVAC2020participant18.200.00044
2014-10-07Development of a Chimpanzee Adenovirus Type 3 Ebolavirus Zaire Vaccine EbolaVaccoordinator15.153.2164
2014-02-01"Proposal to assess an innovative Immunotherapy, based on a thioredox peptide antigen, in a Phase I Trial for Type-1 Diabetes" EXALTcoordinator6.000.0005
2013-12-01"The development of a novel therapeutic vaccine for the selective treatment of the autoimmune disorder, Graves’ disease." DAVIADparticipant5.924.8934
2013-07-01Understanding how immunostimulant combinations in adjuvants synergise to enhance vaccine responses ADJSYNcoordinator169.8001
2013-05-01Exploring the roles and plasticity of T-cell responses in anti-BACterial immunity T-BACcoordinator169.8001
2013-02-01Prevention of hepatitis C virus (HCV) and HIV-1 co-infections through induction of potent T cell responses using prime-boost viral vector vaccine regimens PEACHIparticipant4.388.8135
2011-10-01Advanced Immunization Technologies ADITECparticipant29.980.67052
2010-06-02System for Immunological Modelling as an Ultimate tool to Link Adjuvant function To Adaptive immune responses SIMULATAcoordinator220.5001
2010-01-01Discovery and preclinical development of new generation tuberculosis vaccines NEWTBVACparticipant11.996.73035

Alias institution names:

  • GLAXOSMITHKLINE BIOLOGICALS